
ABSTRACT Background Direct oral anticoagulants (DOAC) have become standard therapy for thrombosis prevention since 2008. Meta‐analyses (MAs) of randomized controlled trials (RCT) are considered high‐level evidence supporting clinical guidelines. However, methodological biases may yield false‐positive findings, particularly through inadequate hypothesis formulation, multiple testing without alpha‐risk correction, and selective outcome reporting. No study has systematically assessed the risk of false positives in MA evaluating DOAC through hypothetico‐deductive reasoning. Objective This study aimed to assess methodological features relevant to confirmatory inference in MA of RCTs evaluating DOACs, including hypothesis specification and multiplicity management, and to quantify nominal exposure to type I error under specified assumptions. Methods Following a pre‐specified protocol, we conducted a meta‐epidemiological study using embase and PubMed databases. We included MA of RCT evaluating four EMA‐approved DOAC. Two independent authors performed study selection. For each MA, we calculated the nominal family‐wise probability of at least one type I error under the global null hypothesis, assuming independent tests. We assessed the presence of directional hypotheses, primary outcome definition, pre‐specified protocols, sensitivity analyses, and spin in conclusions. Results Ninety‐three MA were included (mean 34 118 patients; seven RCT per MA). The median nominal family‐wise type I error probability was 40%, and only 2.2% of MAs reported alpha‐risk management, 26.9% had pre‐specified protocols, and 14.0% reported directional hypotheses. Only 5.4% combined a clearly specified directional hypothesis with a single primary objective and well‐defined outcome. Spin was present in 30.1% of conclusions. Conclusion Most MAs showed substantial uncorrected nominal exposure to multiplicity; this estimate is a theoretical indicator and not the probability that a published conclusion is false. Many MAs also lacked explicit hypotheses and frequently exhibited spin. Strengthening reliability requires integrating genuine hypothetico‐deductive approaches and adapting methodological guidelines.
ABSTRACT Background Airway epithelial cells produce mucus to protect themselves against toxic agents and pathogens. However, excessive mucus accumulation, as seen in chronic obstructive pulmonary disease (COPD), contributes to airway obstruction, inflammation, and reduced efficacy of inhaled therapies. Objectives The aim of the study was to develop an in vitro model for evaluating cytokine production and mucus secretion in human airway epithelial cell lines, with potential application for drug screening. Methods Three human airway epithelial cell lines (A549, Calu‐3, and NCI‐H292) were stimulated for 24 h with cigarette smoke extract (CSE), alone or combined with lipopolysaccharide (LPS). In parallel, NCI‐H292 and Calu‐3 cells were co‐cultured under the same conditions. MUC5AC, CXCL8/IL‐8, CXCL1/GRO‐α, and CCL2/MCP‐1 expression was assessed by RT‐qPCR, and protein secretion by ELISA. MUC5AC production in NCI‐H292 was further evaluated by immunohistochemistry. Results In Calu‐3 cells, stimulation had no significant effect on mucin or cytokine expression. In A549 cells, CSE + LPS induced a marked release of CXCL8/IL‐8, CXCL1/GRO‐α, and CCL2/MCP‐1, but no mucus production. In NCI‐H292 cells, LPS alone increased mucus production, and CSE + LPS had an additive effect on both mucins and cytokines (except CCL2/MCP‐1). In NCI‐H292/Calu‐3 co‐cultures, CSE + LPS enhanced MUC5AC gene expression, whereas LPS alone increased CXCL8/IL‐8 secretion. Conclusion Among the tested cell lines, NCI‐H292 displayed the most consistent dual response in terms of mucus and cytokine production. This supports its use as a practical in vitro model for preliminary screening of therapies targeting airway inflammation and mucus hypersecretion.
ABSTRACT Background Observational studies report that prolonged infusions of piperacillin‐tazobactam may enable the achievement of an optimal clinically targeted free drug concentration above the minimum inhibitory concentration (fT > MIC). Objectives This study aimed to assess the feasibility of a randomized controlled trial (RCT) comparing standard to prolonged infusions of piperacillin‐tazobactam in the obese population. Methods In this open‐label RCT, patients with a body mass index (BMI) of 30 kg/m 2 or higher who initiated piperacillin‐tazobactam were recruited and randomly assigned to receive either standard or prolonged infusions of the antibiotic. Feasibility and safety outcomes were assessed. A blood sample was collected 24 h after the intervention to measure total piperacillin concentrations, with an exploratory aim of determining the proportion of patients who achieved 100% fT > MIC. Results A total of 45 patients were recruited at a rate of 7.2 patients per month with a consent rate of 42.1%, achieving these feasibility objectives. Adherence to blood sampling was 77.8%, below the 80% objective. On an exploratory basis, the proportion of patients who achieved 100% fT > MIC 24 h postintervention was 64.3% in the prolonged‐infusion group and 55.6% in the standard‐infusion group ( p = 0.725). There was no significant difference in the safety outcomes ( p = 0.756). Conclusion This first RCT evaluating prolonged infusions of piperacillin‐tazobactam in the obese population demonstrated the feasibility of the protocol. Although not statistically significant, the results suggest a favorable trend for fT > MIC attainment and no safety signal for prolonged infusions and support the conduct of a larger scale RCT. Trial Registration Clinical trial registration: NCT #06690905
ABSTRACT Background Angiotensin receptor blockers (ARBs) have demonstrated neuroprotective effects in preclinical models of Parkinson's disease (PD), but individual ARBs differ in pharmacological properties that may influence their neuroprotective potential. Objectives Using large‐scale hospital electronic health records of the University of California health system, we tested whether specific ARBs are associated with lower PD risk. Methods We conducted a new‐user, active‐comparator cohort study in the University of California Health Data Warehouse, encompassing 890 712 hypertensive patients across six academic medical centers from 2012 to 2025. Cox proportional hazards models estimated hazard ratios for individual ARB associations with incident PD, adjusting for demographics, nine preindex comorbidities, and index date. Robustness was assessed through propensity score matching and negative‐control analysis. Results Drug‐specific Cox analysis identified irbesartan (HR = 0.588, 95% CI 0.434 to 0.796, p = 0.0006) and olmesartan (HR = 0.797, 95% CI 0.665 to 0.956, p = 0.015) as associated with lower PD risk. Irbesartan survived Bonferroni correction for multiple comparisons, and propensity score matching supported both associations. Conclusion In this large multicenter EHR cohort, irbesartan and olmesartan were associated with lower incident Parkinson's disease risk. These findings support further investigation of the renin‐angiotensin system as a therapeutic target in Parkinson's disease and may inform the development or repurposing of agents with favorable central nervous system penetration and neuroprotective potential.
ABSTRACT Objectives To investigate the influence of sex, age, body weight, smoking habits, and co‐medications on sertraline pharmacokinetics in a routine clinical setting. Methods This retrospective observational study analyzed 177 predominantly inpatient therapeutic drug monitoring records from 101 patients receiving sertraline as monotherapy or polytherapy. Pharmacokinetic parameters—serum concentrations (CSER), concentration‐to‐dose ratio (CDR), weight‐normalized CDR (CDR/kg), apparent clearance (CL/F), and metabolite‐to‐parent ratio (N‐SER/SER)—were compared across subgroups defined by sex, age (< 18; 18–65; > 65 years), BMI, smoking, and co‐medications. To address the nonindependence of repeated measurements, analyses were complemented using linear mixed‐effects models and a sensitivity analysis restricted to one observation per patient. Results Descriptive analyses suggested higher CDR/kg in males and higher CSER in elderly patients. After accounting for within‐patient clustering, the increase in CDR/kg across BMI categories remained the most consistent finding, likely reflecting mathematical normalization. The higher CSER observed in elderly patients persisted in the mixed‐effects model but not in the sensitivity analysis, although the direction of effect remained consistent. Sex‐related differences were not robust after adjustment and were largely attributable to body weight. Smoking showed no measurable effect. Among co‐medications, carbamazepine showed the most consistent pharmacokinetic signal, whereas other findings were less consistent. Conclusion Elderly age may contribute to higher sertraline concentrations; however, its effect appears modest after accounting for clustering. Sex differences are largely explained by body weight, and smoking does not appear to influence pharmacokinetics. Carbamazepine showed a consistent induction pattern, whereas other co‐medication findings should be considered exploratory.